We are pleased to announce that our client, Compugen, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, traded on both Nasdaq and TASE, has raised $79.3M on Nasdaq, in an underwritten follow-on public offering of 8.8M shares (which included partial exercise of the underwriters’ option to purchase additional shares).
The deal was led by partners Lior Aviram and Shelly Blatt Zak and associates Hemi Dagan Shir Sela Pinhas and Ivor Krumholtz.
